{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-22-000111","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.844760+00:00","generated_at":"2026-06-23T06:07:35.422503+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xeris Biopharma enters amended lease for 87,032 sq ft Chicago HQ; base rent $52.50/sq ft","bullets":["Xeris Pharma leases 87,032 sq ft office/lab at 1375 W. Fulton, Chicago; term through 2037.","Annual base rent $52.50/sq ft in year one, escalating 2.5% annually; rent abatement for first 12 months.","Letter of credit increased from $408,263 to $3,247,808 to secure lease obligations.","Company to relocate HQ to premises in H1 2023; current HQ at 180 N. LaSalle to be subleased.","Credit agreement amended to permit issuance of the letter of credit."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-22-000111","json":"https://secwatch.observer/filing/0001867096-22-000111.json","markdown":"https://secwatch.observer/filing/0001867096-22-000111.md","text":"https://secwatch.observer/filing/0001867096-22-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000111/0001867096-22-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709622000111/xers-20220929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:07:35.422503+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}